Insider Trading Review: Codexis, Inc. $CDXS

720949940589d09f6359b1867502319a

Codexis, Inc. (CDXS) insider have most recently took part in a trading activity. On Aug 21, 2015 Yang Patrick Y, Director bought 10,000 shares having total worth of $39,800 at the price of $3.98 per share, following the transaction a total of 348,234 shares owned by Yang Patrick Y. Before this latest buy, Yang Patrick Y purchased CDXS at 3 other times during the past twelve months, for a total investment of $173,200 at an average of $2.89 per share.

Furthermore, over the past 12 months , the stock was traded 5 times by insiders. In 2 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.

Shares of Codexis, Inc. (CDXS) traded up 3.79% on Dec 7, 2017, hitting $6.85. 234,395 shares of the company’s stock traded hands. Codexis, Inc. has a 52 week low of $3.85 and a 52 week high of $7.85. The company’s market cap is $178 million.

Codexis, Inc. (CDXS) last announced its earnings results on Nov 9, 2017. The company reported -0.17 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.17. The company had revenue of $10 million for the quarter, compared to the consensus estimate of $10 million. During the same quarter in the previous year, the company posted 0.09 earnings per share. The company’s revenue for the quarter was down 33% on a year-over-year basis.

2017-11-09 2017-08-09 2017-05-09 2017-03-09 2016-11-08 2016-08-09 2016-05-09 2016-03-03 2015-11-04 2015-08-11
earnings per share -0.17 -0.09 -0.13 -0.07 0.09 0.12 -0.11 -0.05 0.13 -0.14
Revenue(M) 9.98 10.35 7.97 9.97 14.87 16 8 11.59 17.4 6.02

Codexis, Inc. was incorporated in Delaware in January 2002. The Company is a developer of proprietary biocatalysts, which are enzymes or microbes that initiate or accelerate chemical reactions. The Company is currently selling its biocatalysts to customers in the pharmaceutical industry and is engaged in a multi-year research and development collaboration with Equilon Enterprises LLC dba Shell Oil Products US (‘Shell’) to develop advanced biofuels. The Company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. Biocatalysts are enzymes or microbes that initiate or accelerate chemical reactions. It has focused its biocatalyst development efforts on large and rapidly growing markets, including pharmaceuticals and advanced biofuels. It has enabled biocatalyst-based drug manufacturing processes at commercial scale and has delivered biocatalysts and drug products to some of the world’s pharmaceutical companies, including Dr. Reddy’s Laboratories Ltd., Merck & Co., Inc., Pfizer Inc. and Ranbaxy Laboratories Limited. In the Company’s research and development collaboration with Shell, it is developing biocatalysts for use in producing advanced biofuels from renewable sources of non-food plant materials, known as cellulosic biomass. It faces intense competition in the pharmaceuticals market. The Company’s registered and pending U.S. trademarks include Codexis, Codex and Codex Biocatalyst Panel. The Codexis and Codexis design marks have been registered or are pending in selected foreign countries.

William White

William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.

About the Author

William White
William White is a financial writer. He graduated with a degree in Economics. He has contributed to major financial websites and print publications for over 8 years. He handles much of this site's news coverage for corporate insider activity, and occasionally cover other areas of financial sector.